RecruitingNCT04398628
Blood
Von Willebrand Disease
Also known as VWD, von Willebrand disorder, bleeding disorder type 1/2/3
Von Willebrand disease is the most common inherited bleeding disorder, caused by quantitative (types 1 and 3) or qualitative (type 2) defects in von Willebrand factor, a multimeric glycoprotein essential for platelet adhesion and factor VII
ORPHA:903 ↗Gene VWFPrevalence Approximately 1 in 100 for all types combined; severe type 3 affects 1 in 1,000,000Onset Childhood to adolescence (often identified at first hemostatic challenge)Autosomal dominant (types 1 and 2) or autosomal recessive (type 3)
33
studies recruiting now
as of 7 Sept 2026
153
studies registered in total
as of 7 Sept 2026
15
countries with a recruiting site
as of 7 Sept 2026
20 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT07418099
External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis
RecruitingPhase 2NCT07575308
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
RecruitingPhase 3NCT06998524
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
RecruitingNCT07713615
Blood Clotting Markers and Heart Ultrasound in People With Device-Detected Atrial Fibrillation
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 33 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Von Willebrand Disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: VWD Connect Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Von Willebrand Disease
Von Willebrand disease is the most common inherited bleeding disorder, caused by quantitative (types 1 and 3) or qualitative (type 2) defects in von Willebrand factor, a multimeric glycoprotein essential for platelet adhesion and factor VIII stabilization. Type 1 is the mildest form with partial deficiency, type 2 encompasses several subtypes with dysfunctional VWF, and type 3 involves near-complete absence of VWF causing severe bleeding similar to hemophilia. Clinical severity correlates poorly with VWF levels alone and requires comprehensive laboratory evaluation.
Common clinical features
Mucocutaneous bleeding including frequent nosebleeds and easy bruisingProlonged bleeding from minor cuts and woundsHeavy menstrual bleeding (menorrhagia) in femalesBleeding after dental procedures or surgeryGastrointestinal bleeding, particularly in type 2A and 2BJoint bleeds and muscle hematomas in severe type 3Postpartum hemorrhageProlonged bleeding after trauma
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
3 approved treatments and 3 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Von Willebrand Factor Human (Von willebrand factor human component of voncento)Approved: Human Coagulation Factor Viii (Hemofil m)Approved: Vonicog Alfa (Veyvondi)
Phase 3Octocog Alfa (Advate)
Phase 3Tranexamic Acid (Cyklo-f heavy period relief)
Phase 2Rondaptivon Pegol
Before you apply
Things trial teams commonly ask about for Von Willebrand Disease. Not eligibility rules; those are set by each study.
- Specify your VWD subtype (1, 2A, 2B, 2M, 2N, or 3) as trials are often subtype-specific; bring VWF antigen, VWF activity (ristocetin cofactor), and factor VIII levels.
- Type 2B patients may be excluded from some trials due to thrombocytopenia risk with desmopressin; document any desmopressin (DDAVP) response testing results.
- Bleeding Assessment Tool (BAT) scores and bleeding history documentation strengthen trial eligibility assessments for novel VWF replacement or gene therapy studies.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).